OTHER FUNCTIONS: SBIR PHASE I, "MED. ADHERENCE IN HIGHER RISK POPULATIONS," N43D

其他功能：SBIR 第一阶段，“医学。高风险人群的依从性”，N43D

• 批准号: 8554527
• 负责人: Adam Hanina
• 金额: $ 13.79万
• 依托单位: AI CURE TECHNOLOGIES, LLC
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-08-15 至 2013-02-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8554527
• 关键词: Address; Adherence; Code; Computer Vision Systems; Computer software; Computers; Contractor; Coupled; Detection; Development; Devices; Directly Observed Therapy; Effectiveness; Electronics; Elements; Ensure; Film; Generic Drugs; Individual; Intervention; Monitor; Online Systems; Oral; Patients; Pharmaceutical Preparations; Phase; Population; Reporting; Security; Small Business Innovation Research Grant; Solutions; Substance abuse problem; Subutex; System; Tablets; Techniques; Technology; Testing; Trademark; high risk; medication compliance; phase 1 study; population based; programs; software systems; usability

AI Cure Technologies seeks to develop and test the effectiveness and usability of AiView-HR, an automated, population-based medication adherence monitoring system for high-risk, substance abuse populations. AiView-HR will be a significant extension of Ai Cure Technologies' flagship computer-vision product, AiView, incorporating enhanced security sequence elements that will be critical to deploying automated DOT (directly observed therapy) to the high-risk, substance abuse population. Like AiView, AiView-HR will be coupled with a robust web-based dashboard that enables efficient population-based or individual monitoring, review, and intervention of medication adherence.

AI Cure Technologies旨在开发和测试AiView-HR的有效性和可用性，AiView-HR是一种针对高风险药物滥用人群的自动化、基于人群的药物依从性监测系统。AiView-HR将是Ai Cure Technologies的旗舰计算机视觉产品AiView的重要扩展，其中包含增强的安全序列元素，这对于将自动DOT（直接观察治疗）部署到高风险药物滥用人群至关重要。与AiView一样，AiView-HR将与一个强大的基于Web的仪表板相结合，该仪表板可以实现基于人群或个体的有效监测，审查和药物依从性干预。